The clinical benefit rate with cabozantinib was 43.2%. In a recent study, more than 40% of patients with relapsed or refractory germ cell tumors (GCT) experienced a clinical benefit with cabozantinib.

If you’re trying to get pregnant and have spent any time on fertility forums or social media, you’ve probably heard of the two-week wait. Often shortened to TWW, it’s the name given to those anxious ...